Anti-tigit antibodies and methods of use thereof
AssigneeAgenus Inc.
InventorsDhan Sidhartha CHAND, Nicholas Stuart WILSON, Dennis John UNDERWOOD, Benjamin Maxime MORIN
Life of this patent
Estimating the term…
Abstract
The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Claims30
An isolated antibody that specifically binds to human TIGIT, the antibody comprising a heavy chain variable region comprising complementarity determining regions (CDRs) CDRH1, CDRH2, and CDRH3, and a light chain variable region comprising complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein:
- (a) CDRH1 comprises the amino acid sequence of SEQ ID NO:
- 1 or SEQ ID NO:
- 2;
- (b) CDRH2 comprises the amino acid sequence of SEQ ID NO:
- 3 or SEQ ID NO:
- 4;
- (c) CDRH3 comprises the amino acid sequence of SEQ ID NO:
- 5;
- (d) CDRL1 comprises the amino acid sequence of SEQ ID NO:
- 6;
- (e) CDRL2 comprises the amino acid sequence of SEQ ID NO:
- 7;
- and/or
- (f) CDRL3 comprises the amino acid sequence of SEQ ID NO:
- 8.
(canceled)
5-22. (canceled)
24-28. (canceled)
30-31. (canceled)
An isolated antibody that specifically binds to human TIGIT, wherein:
- (a) the antibody binds to the same epitope of human TIGIT as an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 10;
- (b) the antibody binds to an epitope located within a region of human TIGIT, the amino acid sequence of the region consisting of the amino acid sequence of any one of SEQ ID NOs:
- 31-33;
- (c) the antibody binds to one or more amino acid residues of human TIGIT selected from the group consisting of Q35, I47, N49, H90, and T96, numbered according to the amino acid sequence of SEQ ID NO:
- 40;
- (d) the antibody does not bind to one or more of the amino acid residues selected from the group consisting of T34, L52, H55, I56, S57, P58, S59, T98, R100, and F102 of human TIGIT, numbered according to the amino acid sequence of SEQ ID NO:
- 40;
- (e) the binding of the antibody to a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 36, 44, 45, 46, 48, 51, 52, 53, 57, and 59 is substantially weakened relative to the binding of the antibody to a protein comprising the amino acid sequence of SEQ ID NO:
- 42;
- and/or
- (f) the binding of the antibody to a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:
- 43, 47, 49, 54, 55, 56, and 58 is not substantially weakened relative to the binding of the antibody to a protein comprising the amino acid sequence of SEQ ID NO:
- 42.
33-106. (canceled)
108-122. (canceled)
124-128. (canceled)
(canceled)
132-139. (canceled)
146-147. (canceled)
149-168. (canceled)
Dependencies are inferred from the claim text.